Discussion about switch strategy in the adjuvant hormonal therapy of breast cancer: psychological aspects of physician-patient communication

被引:4
作者
Costantini, A. [2 ]
Picardi, A. [7 ]
Zilli, M. [6 ]
Cairoli, F. [2 ]
Torta, R. [1 ]
Marchetti, P. [5 ]
Baile, W. [3 ,4 ]
Iacobelli, S. [6 ]
机构
[1] Univ Turin, Turin, Italy
[2] Univ Roma La Sapienza, St Andrea Hosp, Dept Oncol, Psychoncol Unit, Rome, Italy
[3] Univ Texas MD Anderson Canc Ctr, Dept Behav Sci, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Fac Dev, Houston, TX 77030 USA
[5] Univ Roma La Sapienza, St Andrea Hosp, Dept Oncol, Med Oncol Unit, Rome, Italy
[6] Inter Univ Consortium Biooncol G DAnnunzio, Dept Oncol & Neurosci, Chieti, Italy
[7] Italian Natl Inst Hlth, Ctr Epidemiol Surveillance & Hlth Promot, Mental Hlth Unit, Rome, Italy
关键词
breast cancer; hormonal switch; patient anxiety; physician-patient communication; recurrence risk; POSTMENOPAUSAL WOMEN; ENDOCRINE THERAPY; SKILLS; TAMOXIFEN; EFFICACY; NONADHERENCE; ANASTROZOLE; KNOWLEDGE; NEWS; BAD;
D O I
10.1093/annonc/mdp057
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Materials and methods: A questionnaire, including both closed and open-ended questions, was administered to 70 oncologists. Fifty-one of them returned completely filled questionnaires. Results: Forty-seven percent of the physicians reported difficulties in proposing the hormonal switch, and 60% stated that they found it difficult to make the therapeutic change acceptable to patients. The oncologist's barriers to propose the switch were related mostly to scientific and economic issues, such as the lack of certain advantages of aromatase inhibitors over tamoxifen (28%), their costs (14%) and their side-effects (34%). On the other hand, according to physicians, the patient's barriers to accept the therapeutic change were mainly due to psychological-relational factors, in particular the anxiety produced by the change (40%) and the bad patient-physician communication experienced in the past (26%). Conclusions: Patient-physician communication difficulties about switch strategy in the adjuvant hormonal treatment of breast cancer are, at least in part, related to psychological and relational factors. It is likely that training programs, improving doctor's communication skills, can overcome these problems.
引用
收藏
页码:1647 / 1652
页数:6
相关论文
共 29 条
  • [1] Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
  • [2] Intentional and non-intentional non-adherence to medication amongst breast cancer patients
    Atkins, Louise
    Fallowfield, Lesley
    [J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (14) : 2271 - 2276
  • [3] Efficacy of communication skills training for giving bad news and discussing transitions to palliative care
    Back, Anthony L.
    Arnold, Robert M.
    Baile, Walter F.
    Fryer-Edwards, Kelly A.
    Alexander, Stewart C.
    Barley, Gwyn E.
    Gooley, Ted A.
    Tulsky, James A.
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (05) : 453 - 460
  • [4] Baile WF, 2005, PSYCHO-ONCOL, V14, pS12
  • [5] Treatment decisions for breast carcinoma - Patient preferences and physician perceptions
    Bruera, E
    Willey, JS
    Palmer, JL
    Rosales, M
    [J]. CANCER, 2002, 94 (07) : 2076 - 2080
  • [6] Communications and emotions - Skills and effort are key
    Buckman, R
    [J]. BRITISH MEDICAL JOURNAL, 2002, 325 (7366): : 672 - 672
  • [7] BUCKMAN R, 1992, BREAK BAD NEWS GUIDE, V15
  • [8] Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:: Update of study BIG 1-98
    Coates, Alan S.
    Keshaviah, Aparna
    Thuerlimann, Beat
    Mouridsen, Henning
    Mauriac, Louis
    Forbes, John F.
    Paridaens, Robert
    Castiglione-Gertsch, Monica
    Gelber, Richard D.
    Colleoni, Marco
    Lang, Istvan
    Del Mastro, Lucia
    Smith, Ian
    Chirgwin, Jacquie
    Nogaret, Jean-Marie
    Pienkowski, Tadeusz
    Wardley, Andrew
    Jakobsen, Erik H.
    Price, Karen N.
    Goldhirsch, Aron
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) : 486 - 492
  • [9] Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
    Coombes, R. C.
    Kilburn, L. S.
    Snowdon, C. F.
    Paridaens, R.
    Coleman, R. E.
    Jones, S. E.
    Jassem, J.
    Van de Velde, C. J. H.
    Delozier, T.
    Alvarez, I.
    Del Mastro, L.
    Ortmann, O.
    Diedrich, K.
    Coates, A. S.
    Bajetta, E.
    Holmberg, S. B.
    Dodwell, D.
    Mickiewicz, E.
    Andersen, J.
    Lonning, P. E.
    Cocconi, G.
    Forbes, J.
    Castiglione, M.
    Stuart, N.
    Stewart, A.
    Fallowfield, L. J.
    Bertelli, G.
    Hall, E.
    Bogle, R. G.
    Carpentieri, M.
    Colajori, E.
    Subar, M.
    Ireland, E.
    Bliss, J. M.
    [J]. LANCET, 2007, 369 (9561) : 559 - 570
  • [10] COSTANTINI A, J CANC ED IN PRESS